IMD-1-0240 © 2005
Leleux, Benoit, F; Pahwa, Atul
Enterprise Valuation runs an independent valuation of Genedata; a Swiss start-up company to be able to help Novartis Venture Fund examine and structure the next funding round. Enterprise Valuation; under a tight investment timeframe; has to customize the evaluation process; using both quantitative and qualitative data; to fulfill the customers needs.
The case summarizes competitive positioning; its product portfolio; Genedata’s history; and dilemmas that it'll need to cope with in the not too distant future. Learning Objective: This case a part of a three case series meant to draw the audience into the problems surrounding the valuation of a startup biotechnology company; one of the most insecure and volatile market.
Subjects: Biotechnology; Valuation; Start-up; Entrepreneurship; Pharmaceuticals; Genomics; Software; Development Stage enterprise
Settings: Basel; Switzerland; Biotechnology; Pharmaceutical; Start up; 2000-2005
Related Case Solutions & Analyses:
Miami Car Care Center Inc.
STARTEGIC PLAN
Montreaux Chocolate
CAFÉ D. POWND
Diamond Chemicals Public Limited Corporation
Daktronics Dividend Policy in 2010
Buffett’s Bid for Media General’s Newspapers
Smith Family Financial Planning
Walt Disney Company’s Yen Financing, Spanish Version
Diversification, the Capital Asset Pricing Model, and the Cost of Equity Capital, Spanish Version
